Design
Review
Supports vigilant warfarin monitoring with polypharmacy; leaves open optimal evidence-based strategies for diverse regimens.
Remaining vigilant for interactions between medications is a formidable challenge for several reasons. The science of drug interactions is dauntingly complex and constantly evolving, the patient's medication list is often a moving target with prescription and nonprescription elements, and dozens of
No takes yet. Share an insight, caveat, or question.
David N. Juurlink (2007) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: